IPAC Text Size (+ / -) IPAC Links IPAC Sitemap IPAC Members Area IPAC Contact Us IPAC Search


Click here for presentations and posters from the IPAC-RS 2011 Conference

 

Welcome to IPAC-RS. We are an international association of innovator and generic companies that develop, manufacture or market orally inhaled and nasal drug products for local and systemic treatment of a variety of debilitating diseases such as asthma, chronic obstructive pulmonary disease and diabetes.

We are committed to advancing consensus-based, scientifically driven standards and regulations for these products, with the purpose of facilitating the availability of high-quality, safe, and efficacious drug products to patients.



IPAC-RS 2011 - 2013 Strategic Plan

IPAC-RS 2011-2013 Strategic Plan (Chinese version)

IPAC-RS Press Releases

Baseline Requirements Document

The IPAC-RS OINDP Materials Working Group has worked with suppliers to develop baseline requirements for materials used to manufacture components for OINDP. The impetus for this document was based on requests for a uniform set of requirements arising from several discussions between pharmaceutical manufacturers, regulators and multiple suppliers in meetings sponsored by IPAC-RS. As there is no single guidance for these types of materials, these requirements were compiled from a variety of international regulatory and compendial guidelines and standards. A copy of the Baseline Requirements for Materials used in Orally Inhaled and Nasal Drug Products (OINDP) is available here: Baseline Requirements.


IPAC-RS 2011 Conference: Bringing Value to the Patient in a Changing World

On 29-30-31 March 2011 IPAC-RS hosted a three-day event. Presentations, posters, and a Conference Report are posted here: 2011 IPAC-RS Conference.


IPAC-RS Satellite Conference at RDD Europe 2011: Perspectives on Efficient Data Analysis Methods and Abbreviated Impactor Measurements as Quality Assessment Tools

IPAC-RS hosted a Satellite Conference on Friday, 6 May 2011 at RDD Europe 2011, which included short presentations from representatives of regulatory agencies, pharmacopeias and industry followed by interactive discussions with the audience around technical and statistical aspects of EDA and AIM, and the lifecycle approach to incorporating EDA and AIM in product development, registration and manufacturing.

Presentations and a Summary Report are posted at Cascade Impaction Working Group.

Our members include:

3M
AstraZeneca
Boehringer Ingelheim
Catalent
Chiesi
GlaxoSmithKline
MannKind Corporation
Merck & Co., Inc.
Novartis
Pfizer
Teva
Vectura Ltd.

In addition, the following suppliers of device components for orally inhaled and nasal drug products participate in the Supplier Quality Control Initiative of IPAC-RS:

Aptar Pharma
Rexam
SHL Group
West

 

Copyright (c) IPAC-RS 2007
Privacy Policy and Disclaimers

Webmaster : Internet Business Solutions